Differentiation between emerging non-steroidal and established steroidal mineralocorticoid receptor antagonists: head-to-head comparisons of pharmacological and clinical characteristics
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Differentiation between emerging non-steroidal and established steroidal mineralocorticoid receptor antagonists: head-to-head comparisons of pharmacological and clinical characteristics
Authors
Keywords
-
Journal
EXPERT OPINION ON INVESTIGATIONAL DRUGS
Volume 30, Issue 11, Pages 1141-1157
Publisher
Informa UK Limited
Online
2021-11-11
DOI
10.1080/13543784.2021.2002844
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Proteomic and Mechanistic Analysis of Spironolactone in Patients at Risk for HF
- (2021) João Pedro Ferreira et al. JACC-Heart Failure
- Effect of KBP-5074 on Blood Pressure in Advanced Chronic Kidney Disease: Results of the BLOCK-CKD Study
- (2021) George Bakris et al. HYPERTENSION
- Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes
- (2021) Bertram Pitt et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Non-Steroidal Mineralocorticoid Receptor Antagonist KBP-5074 Limits Albuminuria and has Improved Therapeutic Index Compared With Eplerenone in a Rat Model With Mineralocorticoid-Induced Renal Injury
- (2021) Frédéric Jaisser et al. Frontiers in Pharmacology
- Crystal structure of the mineralocorticoid receptor ligand‐binding domain in complex with a potent and selective nonsteroidal blocker, esaxerenone (CS‐3150)
- (2020) Mizuki Takahashi et al. FEBS LETTERS
- Unravelling the interplay between hyperkalaemia, renin-angiotensin-aldosterone inhibitor use and clinical outcomes. Data from 9222 chronic heart failure patients of the ESC-HFA-EORP Heart Failure Long-Term Registry
- (2020) Patrick Rossignol et al. EUROPEAN JOURNAL OF HEART FAILURE
- Apararenone in patients with diabetic nephropathy: results of a randomized, double-blind, placebo-controlled phase 2 dose–response study and open-label extension study
- (2020) Takashi Wada et al. Clinical and Experimental Nephrology
- Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine
- (2020) Rajiv Agarwal et al. EUROPEAN HEART JOURNAL
- Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes
- (2020) George L. Bakris et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phase 1 Studies to Define the Safety, Tolerability, and Pharmacokinetic and Pharmacodynamic Profiles of the Nonsteroidal Mineralocorticoid Receptor Antagonist Apararenone in Healthy Volunteers
- (2020) Tadakatsu Nakamura et al. Clinical Pharmacology in Drug Development
- Finerenone and Cardiovascular Outcomes in Patients with Chronic Kidney Disease and Type 2 Diabetes
- (2020) Gerasimos Filippatos et al. CIRCULATION
- Esaxerenone (CS-3150) in Patients with Type 2 Diabetes and Microalbuminuria (ESAX-DN)
- (2020) Sadayoshi Ito et al. Clinical Journal of the American Society of Nephrology
- Antihypertensive effects and safety of esaxerenone in patients with moderate kidney dysfunction
- (2020) Sadayoshi Ito et al. HYPERTENSION RESEARCH
- Effect of a novel nonsteroidal selective mineralocorticoid receptor antagonist, esaxerenone (CS-3150), on blood pressure and renal injury in high salt-treated type 2 diabetic mice
- (2019) Abdus Sattar Bhuiyan et al. HYPERTENSION RESEARCH
- Identification of Mineralocorticoid Receptor Modulators with Low Impact on Electrolyte Homeostasis but Maintained Organ Protection
- (2019) Kenneth Granberg et al. JOURNAL OF MEDICINAL CHEMISTRY
- The selective mineralocorticoid receptor modulator AZD9977 reveals differences in mineralocorticoid effects of aldosterone and fludrocortisone
- (2019) Krister Bamberg et al. JOURNAL OF THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM
- Efficacy and safety of esaxerenone (CS-3150) for the treatment of essential hypertension: a phase 2 randomized, placebo-controlled, double-blind study
- (2019) Sadayoshi Ito et al. JOURNAL OF HUMAN HYPERTENSION
- New mineralocorticoid receptor antagonists: update on their use in chronic kidney disease and heart failure
- (2019) Irene Capelli et al. JOURNAL OF NEPHROLOGY
- Efficacy and Safety of Esaxerenone (CS-3150) for the Treatment of Type 2 Diabetes with Microalbuminuria
- (2019) Sadayoshi Ito et al. Clinical Journal of the American Society of Nephrology
- Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trial
- (2019) Rajiv Agarwal et al. LANCET
- Population Pharmacokinetic and Exposure–Response Analysis of Finerenone: Insights Based on Phase IIb Data and Simulations to Support Dose Selection for Pivotal Trials in Type 2 Diabetes with Chronic Kidney Disease
- (2019) Nelleke Snelder et al. CLINICAL PHARMACOKINETICS
- Safety, Tolerability, and Pharmacokinetics of the Mineralocorticoid Receptor Modulator AZD9977 in Healthy Men: A Phase I Multiple Ascending Dose Study
- (2019) Andrew Whittaker et al. CTS-Clinical and Translational Science
- Double-Blind Randomized Phase 3 Study Comparing Esaxerenone (CS-3150) and Eplerenone in Patients With Essential Hypertension (ESAX-HTN Study)
- (2019) Sadayoshi Ito et al. HYPERTENSION
- Effects of mineralocorticoid receptor antagonists in proteinuric kidney disease
- (2019) Maria-Eleni Alexandrou et al. JOURNAL OF HYPERTENSION
- Clinical safety, tolerability, pharmacokinetics and effects on urinary electrolyte excretion of AZD9977, a novel, selective mineralocorticoid receptor modulator
- (2018) Fredrik Erlandsson et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Single- and multiple-dose escalation study to assess pharmacokinetics, pharmacodynamics and safety of oral esaxerenone in healthy Japanese subjects
- (2018) Manabu Kato et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Data-Driven Approach to Identify Subgroups of Heart Failure With Reduced Ejection Fraction Patients With Different Prognoses and Aldosterone Antagonist Response Patterns
- (2018) João Pedro Ferreira et al. Circulation-Heart Failure
- Incidence, predictors and clinical management of hyperkalaemia in new users of mineralocorticoid receptor antagonists
- (2018) Marco Trevisan et al. EUROPEAN JOURNAL OF HEART FAILURE
- Selective Mineralocorticoid Receptor Cofactor Modulation as Molecular Basis for Finerenone’s Antifibrotic ActivityNovelty and Significance
- (2018) Jana Grune et al. HYPERTENSION
- Preclinical pharmacology of AZD9977: A novel mineralocorticoid receptor modulator separating organ protection from effects on electrolyte excretion
- (2018) Krister Bamberg et al. PLoS One
- Biotransformation of Finerenone, a Novel Nonsteroidal Mineralocorticoid Receptor Antagonist, in Dogs, Rats, and Humans, In Vivo and In Vitro
- (2018) Michael Gerisch et al. DRUG METABOLISM AND DISPOSITION
- Comparison of effects of aldosterone receptor antagonists spironolactone and eplerenone on cardiovascular outcomes and safety in patients with acute decompensated heart failure
- (2018) Masayoshi Yamamoto et al. HEART AND VESSELS
- Pharmacokinetics, Metabolism, and Excretion of [14C]Esaxerenone, a Novel Mineralocorticoid Receptor Blocker in Humans
- (2018) Makiko Yamada et al. DRUG METABOLISM AND DISPOSITION
- Macrophage Mineralocorticoid Receptor Is a Pleiotropic Modulator of Myocardial Infarct Healing
- (2018) Daniela Fraccarollo et al. HYPERTENSION
- Pathophysiological mechanisms of mineralocorticoid receptor-dependent cardiovascular and chronic kidney disease
- (2018) Akira Nishiyama HYPERTENSION RESEARCH
- 30 YEARS OF THE MINERALOCORTICOID RECEPTOR: Nongenomic effects via the mineralocorticoid receptor
- (2017) Stefanie Ruhs et al. JOURNAL OF ENDOCRINOLOGY
- 30 YEARS OF THE MINERALOCORTICOID RECEPTOR: Mineralocorticoid receptor antagonists: 60 years of research and development
- (2017) Peter Kolkhof et al. JOURNAL OF ENDOCRINOLOGY
- A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease
- (2016) Gerasimos Filippatos et al. EUROPEAN HEART JOURNAL
- Pharmacokinetics, safety and tolerability of the novel, selective mineralocorticoid receptor antagonist finerenone - results from first-in-man and relative bioavailability studies
- (2016) Silvia Lentini et al. FUNDAMENTAL & CLINICAL PHARMACOLOGY
- Steroidal and Nonsteroidal Mineralocorticoid Receptor Antagonists Cause Differential Cardiac Gene Expression in Pressure Overload-induced Cardiac Hypertrophy
- (2016) Jana Grune et al. JOURNAL OF CARDIOVASCULAR PHARMACOLOGY
- Pharmacokinetics, distribution, and disposition of esaxerenone, a novel, highly potent and selective non-steroidal mineralocorticoid receptor antagonist, in rats and monkeys
- (2016) Makiko Yamada et al. XENOBIOTICA
- Aldosterone Blockade in CKD: Emphasis on Pharmacology
- (2015) Michael H. Schwenk et al. ADVANCES IN CHRONIC KIDNEY DISEASE
- Pharmacological profile of CS-3150, a novel, highly potent and selective non-steroidal mineralocorticoid receptor antagonist
- (2015) Kiyoshi Arai et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- CS-3150, a novel non-steroidal mineralocorticoid receptor antagonist, prevents hypertension and cardiorenal injury in Dahl salt-sensitive hypertensive rats
- (2015) Kiyoshi Arai et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Comparison of eplerenone and spironolactone for the treatment of primary aldosteronism
- (2015) Shigehiro Karashima et al. HYPERTENSION RESEARCH
- Finerenone Impedes Aldosterone-dependent Nuclear Import of the Mineralocorticoid Receptor and Prevents Genomic Recruitment of Steroid Receptor Coactivator-1
- (2015) Larbi Amazit et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Finerenone, a Novel Selective Nonsteroidal Mineralocorticoid Receptor Antagonist Protects From Rat Cardiorenal Injury
- (2014) Peter Kolkhof et al. JOURNAL OF CARDIOVASCULAR PHARMACOLOGY
- Incidence, Determinants, and Prognostic Significance of Hyperkalemia and Worsening Renal Function in Patients With Heart Failure Receiving the Mineralocorticoid Receptor Antagonist Eplerenone or Placebo in Addition to Optimal Medical Therapy
- (2013) Patrick Rossignol et al. Circulation-Heart Failure
- Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial
- (2013) Bertram Pitt et al. EUROPEAN HEART JOURNAL
- Discovery of BAY 94-8862: A Nonsteroidal Antagonist of the Mineralocorticoid Receptor for the Treatment of Cardiorenal Diseases
- (2012) Lars Bärfacker et al. ChemMedChem
- The Ubiquitous Mineralocorticoid Receptor: Clinical Implications
- (2012) Urseline A. Hawkins et al. CURRENT HYPERTENSION REPORTS
- Rationale and design of ARTS: a randomized, double-blind study of BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease
- (2012) Bertram Pitt et al. EUROPEAN JOURNAL OF HEART FAILURE
- Cardiorenal End Points in a Trial of Aliskiren for Type 2 Diabetes
- (2012) Hans-Henrik Parving et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effects of olmesartan on renal and cardiovascular outcomes in type 2 diabetes with overt nephropathy: a multicentre, randomised, placebo-controlled study
- (2011) E. Imai et al. DIABETOLOGIA
- A double-blind, randomized study comparing the antihypertensive effect of eplerenone and spironolactone in patients with hypertension and evidence of primary aldosteronism
- (2011) Hari K Parthasarathy et al. JOURNAL OF HYPERTENSION
- Molecular pharmacology of the mineralocorticoid receptor: Prospects for novel therapeutics
- (2011) Peter Kolkhof et al. MOLECULAR AND CELLULAR ENDOCRINOLOGY
- A New Mode of Mineralocorticoid Receptor Antagonism by a Potent and Selective Nonsteroidal Molecule
- (2010) Jérôme Fagart et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms
- (2010) Faiez Zannad et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Comparison of the Aldosterone-blocking Agents Eplerenone and Spironolactone
- (2008) Allan Struthers et al. CLINICAL CARDIOLOGY
- Spironolactone versus eplerenone for the treatment of idiopathic hyperaldosteronism
- (2008) Asterios Karagiannis et al. EXPERT OPINION ON PHARMACOTHERAPY
- Telmisartan, Ramipril, or Both in Patients at High Risk for Vascular Events
- (2008) NEW ENGLAND JOURNAL OF MEDICINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started